Signal detection in post-marketing surveillance for controlled substances - PubMed (original) (raw)
Review
. 2009 Dec 1:105 Suppl 1:S33-41.
doi: 10.1016/j.drugalcdep.2009.05.019. Epub 2009 Jul 18.
Affiliations
- PMID: 19616902
- DOI: 10.1016/j.drugalcdep.2009.05.019
Review
Signal detection in post-marketing surveillance for controlled substances
Nabarun Dasgupta et al. Drug Alcohol Depend. 2009.
Abstract
Signal detection for pharmaceutical controlled substances presents unique challenges compared to other pharmacovigilance programs because risks are present in the patient and non-patient populations. Defining signals for controlled substances has been difficult because no specific empirical criteria have been established through regulatory actions or guidances. We start with a review of data sources available for decision making to regulators and industry. In this paper we present a framework for processing signals received during post-marketing surveillance: signal identification, verification and assessment, followed by intervention and evaluation. Signal identification involves processing qualitative and quantitative information in order to generate hypotheses describing concerns with controlled substances. Integration of heterogeneous data sources makes this process difficult and we describe multiple approaches utilized in practice today. Signal verification currently relies heavily on telephone interviews with stakeholders in local communities. Once information on a potential signal has been gathered signal assessment is a higher order process conducted with an eye towards broader societal expectations and the ability to intervene or further study the problem. Intervention and evaluation complete the cycle of signal assessment and triage. This paper is intended as a primer of the current practice of signal assessment in the post-marketing surveillance for controlled substances.
Similar articles
- Monitoring risk: post marketing surveillance and signal detection.
Dart RC. Dart RC. Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S26-32. doi: 10.1016/j.drugalcdep.2009.08.011. Epub 2009 Sep 12. Drug Alcohol Depend. 2009. PMID: 19748743 - Risk management and post-marketing surveillance of CNS drugs.
Henningfield JE, Schuster CR. Henningfield JE, et al. Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S56-64. doi: 10.1016/j.drugalcdep.2009.08.004. Epub 2009 Sep 19. Drug Alcohol Depend. 2009. PMID: 19767155 - National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
Butler SF, Budman SH, Licari A, Cassidy TA, Lioy K, Dickinson J, Brownstein JS, Benneyan JC, Green TC, Katz N. Butler SF, et al. Pharmacoepidemiol Drug Saf. 2008 Dec;17(12):1142-54. doi: 10.1002/pds.1659. Pharmacoepidemiol Drug Saf. 2008. PMID: 18932173 - Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials. EFSA GMO Panel Working Group on Animal Feeding Trials. Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Food Chem Toxicol. 2008. PMID: 18328408 Review. - Decision support methods for the detection of adverse events in post-marketing data.
Hauben M, Bate A. Hauben M, et al. Drug Discov Today. 2009 Apr;14(7-8):343-57. doi: 10.1016/j.drudis.2008.12.012. Epub 2009 Jan 31. Drug Discov Today. 2009. PMID: 19187799 Review.
Cited by
- Invited Commentary: Drug Checking for Novel Insights Into the Unregulated Drug Supply.
Dasgupta N, Figgatt MC. Dasgupta N, et al. Am J Epidemiol. 2022 Jan 24;191(2):248-252. doi: 10.1093/aje/kwab233. Am J Epidemiol. 2022. PMID: 34528056 Free PMC article. - Postmarketing surveillance for "modified-risk" tobacco products.
O'Connor RJ. O'Connor RJ. Nicotine Tob Res. 2012 Jan;14(1):29-42. doi: 10.1093/ntr/ntq243. Epub 2011 Jan 20. Nicotine Tob Res. 2012. PMID: 21330282 Free PMC article. Review. - Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis.
Anderson LS, Bell HG, Gilbert M, Davidson JE, Winter C, Barratt MJ, Win B, Painter JL, Menone C, Sayegh J, Dasgupta N. Anderson LS, et al. JMIR Public Health Surveill. 2017 Feb 1;3(1):e6. doi: 10.2196/publichealth.6174. JMIR Public Health Surveill. 2017. PMID: 28148472 Free PMC article. - Multiple Determinants of Specific Modes of Prescription Opioid Diversion.
Cicero TJ, Kurtz SP, Surratt HL, Ibanez GE, Ellis MS, Levi-Minzi MA, Inciardi JA. Cicero TJ, et al. J Drug Issues. 2011 Spring;41(2):283-304. doi: 10.1177/002204261104100207. J Drug Issues. 2011. PMID: 22287798 Free PMC article. - Conference on abuse liability and appeal of tobacco products: conclusions and recommendations.
Henningfield JE, Hatsukami DK, Zeller M, Peters E. Henningfield JE, et al. Drug Alcohol Depend. 2011 Jul 1;116(1-3):1-7. doi: 10.1016/j.drugalcdep.2010.12.009. Epub 2011 Mar 3. Drug Alcohol Depend. 2011. PMID: 21376479 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical